Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
84 participants
INTERVENTIONAL
2011-10-31
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
What is not known is whether there is any extra benefit of combining soy protein and isoflavones with cocoa.
The aim of the study is to look at the modification of cardiovascular risk by soy and/or cocoa in patients with type 2 diabetes, alone or in combination.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Comparison Chocolate With and Without High Cocoa Solids in Patients With Type 2 Diabetes in a Randomised Clinical Trial
NCT01617603
Macro- and Microvascular Response to Cocoa Flavanols in Healthy and Type 2 Diabetes
NCT05449782
Cocoa Polyphenols and Postprandial Metabolism in Type 2 Diabetes
NCT01886989
Effect of Flavanol-rich Cocoa on Peripheral and Cerebral Blood Flow in Type 2 Diabetes
NCT01654172
The Effect of Cocoa Flavanol on the BOLD Response and Cognitive Function in Type 1 Diabetes
NCT03452605
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The target number of participants is 100. All participants are patients with type 2 diabetes on diet alone or metformin treatment. Participants will be asked to eat two soy bars daily for 8 weeks. The length of the study is 10 weeks and involves 4 visits at the Diabetes Research Centre in Hull, UK.
The bars will contain:
* soy protein alone, or
* soy protein with additional isoflavones, or
* soy protein with cocoa, or
* soy protein with isoflavones and cocoa, or
* placebo bars without soy protein, isoflavones or cocoa.
The study is randomised (a computer based allocation schema will be used to decide which bars the participant will need to consume). Participants have the same 20% chance to be participant of any of the above groups. The study is placebo-controlled (there is one arm of placebo bars without soy protein, additional isoflavones or cocoa). The study is double-blind (neither the participants or the research team will know which bars they will take).
2. Study-specific procedures
Visit 1 (week 0). Non-fasting visit. Interested participants discuss the study with a member of the study team who will explain each aspect of the study, following which informed consent will be then obtained. Subsequently, blood pressure, weight, height and waist circumference will be measured, medical history and list of medication are recorded, and blood is taken to determine eligibility. A dietitian will explain about eating a normal diet and the foods we would like the participants to avoid during the study. Vegetarian patients may include too much soy in the diet and for this reason they will not be able to take part in the study. All participants will be non smokers.
Visit 2 (week 2)and Visit 4 (week 10). Fasting visits. Fasting blood is taken and the EndoPAT is performed. Weight, height and waist circumference measurement performed. The EndoPAT test takes between 20-30 minutes. The first box of study bars is dispensed during visit 2. Participants need to consume two bars daily. All remaining uneaten bars and empty wrappers will be collected during visit 4.
Visit 3 (week 6). Non-fasting visit. Height, weight, abdominal circumference, blood pressure are measured. Second box of study bars is dispensed.
Participants are asked to complete a one week food diary and a three day hunger questionnaire before the fasting blood tests. The food diary includes mood rating scales to assess the effect of the consumption of the bars on mood. Participants need to complete these prior to Visit 2 and visit 4.
Participants have 24 hours blood pressure measurement prior to Visit 2 and Visit 4.
24 hours urine collection also takes place prior to visit 2 and visit 4.
3\. Optional test incorporated into the study: Body Volume Index measurement Based on participants preference, Body Volume Index measurement is offered as a complementary tool to assess body shape and weight.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Soy protein with isoflavones and cocoa
Soy protein with isoflavones and cocoa bars. 2 bars daily for 8 weeks.
Soy protein
2 bars daily for 8 weeks.
Isoflavones
2 bars daily for 8 weeks.
Cocoa
2 bars daily for 8 weeks.
Soy protein alone with cocoa
Soy protein alone with cocoa with no isoflavones. 2 bars daily for 8 weeks.
Soy protein
2 bars daily for 8 weeks.
Cocoa
2 bars daily for 8 weeks.
Soy protein with soy isoflavones
Soy protein with isoflavones bar. 2 bars daily for 8 weeks.
Soy protein
2 bars daily for 8 weeks.
Isoflavones
2 bars daily for 8 weeks.
Soy protein alone
Soy protein alone without soy isoflavone or cocoa polyphenol. 2 bars daily for 8 weeks.
Soy protein
2 bars daily for 8 weeks.
Placebo
Placebo bar without soy protein, isoflavones or cocoa polyphenols. 2 bars daily for 8 weeks
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Soy protein
2 bars daily for 8 weeks.
Isoflavones
2 bars daily for 8 weeks.
Cocoa
2 bars daily for 8 weeks.
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stable medication history for 3 months prior to screening visit
* Age 45-80
Exclusion Criteria
* Patients not wishing to allow disclosure to their GPs
* Pre-menopausal women or on hormone replacement therapy
* HbA1c \>9% at screening
* Patients with known food allergies
* Smokers
* Vegans and vegetarians
45 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Hull
OTHER
Hull University Teaching Hospitals NHS Trust
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephen Atkin
Role: PRINCIPAL_INVESTIGATOR
University of Hull
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Michael White Diabetes Centre
Hull, North Humberside, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Anderson JW, Smith BM, Washnock CS. Cardiovascular and renal benefits of dry bean and soybean intake. Am J Clin Nutr. 1999 Sep;70(3 Suppl):464S-474S. doi: 10.1093/ajcn/70.3.464s.
Vedavanam K, Srijayanta S, O'Reilly J, Raman A, Wiseman H. Antioxidant action and potential antidiabetic properties of an isoflavonoid-containing soyabean phytochemical extract (SPE). Phytother Res. 1999 Nov;13(7):601-8. doi: 10.1002/(sici)1099-1573(199911)13:73.0.co;2-o.
Lee DS, Lee SH. Genistein, a soy isoflavone, is a potent alpha-glucosidase inhibitor. FEBS Lett. 2001 Jul 13;501(1):84-6. doi: 10.1016/s0014-5793(01)02631-x.
Sorenson RL, Brelje TC, Roth C. Effect of tyrosine kinase inhibitors on islets of Langerhans: evidence for tyrosine kinases in the regulation of insulin secretion. Endocrinology. 1994 Apr;134(4):1975-8. doi: 10.1210/endo.134.4.8137766.
Wagner JD, Cefalu WT, Anthony MS, Litwak KN, Zhang L, Clarkson TB. Dietary soy protein and estrogen replacement therapy improve cardiovascular risk factors and decrease aortic cholesteryl ester content in ovariectomized cynomolgus monkeys. Metabolism. 1997 Jun;46(6):698-705. doi: 10.1016/s0026-0495(97)90016-0.
Duncan AM, Underhill KE, Xu X, Lavalleur J, Phipps WR, Kurzer MS. Modest hormonal effects of soy isoflavones in postmenopausal women. J Clin Endocrinol Metab. 1999 Oct;84(10):3479-84. doi: 10.1210/jcem.84.10.6067.
Goodman-Gruen D, Kritz-Silverstein D. Usual dietary isoflavone intake is associated with cardiovascular disease risk factors in postmenopausal women. J Nutr. 2001 Apr;131(4):1202-6. doi: 10.1093/jn/131.4.1202.
Hermansen K, Sondergaard M, Hoie L, Carstensen M, Brock B. Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects. Diabetes Care. 2001 Feb;24(2):228-33. doi: 10.2337/diacare.24.2.228.
Tsai AC, Vinik AI, Lasichak A, Lo GS. Effects of soy polysaccharide on postprandial plasma glucose, insulin, glucagon, pancreatic polypeptide, somatostatin, and triglyceride in obese diabetic patients. Am J Clin Nutr. 1987 Mar;45(3):596-601. doi: 10.1093/ajcn/45.3.596.
Jayagopal V, Albertazzi P, Kilpatrick ES, Howarth EM, Jennings PE, Hepburn DA, Atkin SL. Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes. Diabetes Care. 2002 Oct;25(10):1709-14. doi: 10.2337/diacare.25.10.1709.
Chedraui P, San Miguel G, Hidalgo L, Morocho N, Ross S. Effect of Trifolium pratense-derived isoflavones on the lipid profile of postmenopausal women with increased body mass index. Gynecol Endocrinol. 2008 Nov;24(11):620-4. doi: 10.1080/09513590802288283.
Scholey AB, French SJ, Morris PJ, Kennedy DO, Milne AL, Haskell CF. Consumption of cocoa flavanols results in acute improvements in mood and cognitive performance during sustained mental effort. J Psychopharmacol. 2010 Oct;24(10):1505-14. doi: 10.1177/0269881109106923. Epub 2009 Nov 26.
Konya J, Sathyapalan T, Kilpatrick ES, Atkin SL. The Effects of Soy Protein and Cocoa With or Without Isoflavones on Glycemic Control in Type 2 Diabetes. A Double-Blind, Randomized, Placebo-Controlled Study. Front Endocrinol (Lausanne). 2019 May 9;10:296. doi: 10.3389/fendo.2019.00296. eCollection 2019.
Related Links
Access external resources that provide additional context or updates about the study.
publication link
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R1188
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.